All In Biotech

Drug Trial Radar · NCT06916806

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

May 5, 2027

Study completion Sep 15, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Fortrea
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. • Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1), twice (Part 2a), or three times (Part 2b).

Conditions

  • Systemic Lupus Erythematosus
  • Idiopathic Inflammatory Myopathies
  • Rheumatoid Arthritis

Interventions

  • AZD5492Drug

    IMP: subcutaneous.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events.Time frame: Day 1 to end of the study (up to 52 weeks)
  2. Safety evaluation of AZD5492: Number of participants with related treatment-emergent adverse events.Time frame: Day 1 to end of the study (up to 52 weeks)
  3. Safety evaluation of AZD5492: Frequency of dose limiting toxicities (DLTs).Time frame: Day 1 to end of the study (up to 52 weeks)
  4. Safety evaluation of AZD5492: Number of SAEs leading to deathTime frame: Day 1 to end of the study (up to 52 weeks)
  5. Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events by grade.Time frame: Day 1 to end of the study (up to 52 weeks)
  6. Tolerability evaluation of AZD5492: Number of participants with treatment-emergent vital signs abnormalities.Time frame: Day 1 to end of the study (up to 52 weeks)
  7. Tolerability evaluation of AZD5492: Number of participants with treatment-emergent clinical laboratory abnormalities.Time frame: Day 1 to end of the study (up to 52 weeks)
  8. Tolerability evaluation of AZD5492: Number of participants with abnormal ECG.Time frame: From Day 1 up to Day 180

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama · Recruiting

  • Research Site

    Birmingham, Alabama · Withdrawn

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Sacramento, California · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Recruiting

  • Research Site

    Omaha, Nebraska · Not yet recruiting

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Hamilton, Ontario, Canada · Recruiting

  • Research Site

    Sherbrooke, Quebec, Canada · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Wuhan, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Bordeaux, France · Recruiting

  • Research Site

    Montpellier, France · Recruiting

  • Research Site

    Nancy, France · Recruiting

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Strasbourg, France · Recruiting

  • Research Site

    Toulouse, France · Recruiting

  • Research Site

    Cologne, Germany · Recruiting

  • Research Site

    Erlangen, Germany · Recruiting

  • Research Site

    Magdeburg, Germany · Recruiting

  • Research Site

    Pok Fu Lam, Hong Kong · Recruiting

  • Research Site

    Bunkyō City, Japan · Recruiting

  • Research Site

    Kita-gun, Japan · Recruiting

  • Research Site

    Kitakyushu-shi, Japan · Recruiting

  • Research Site

    Kyoto, Japan · Recruiting

  • Research Site

    Nagasaki, Japan · Recruiting

  • Research Site

    Amsterdam, Netherlands · Recruiting

  • Research Site

    Leiden, Netherlands · Withdrawn

  • Research Site

    Mérida, Spain · Recruiting

  • Research Site

    Seville, Spain · Recruiting

  • Research Site

    Valladolid, Spain · Recruiting

  • Research Site

    Glasgow, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.